Cemiplimab for adjuvant treatment of high-risk cutaneous squamous cell carcinoma after surgery and radiotherapy [ID6659]Status:In development | In consultationProgramme:Technology appraisal guidanceConsultation end date: 19 February 2026Expected publication date: TBC